Peptide Degradation: Oxidation, Deamidation, and Hydrolysis

Peptide instability is not random. A small number of well-characterised chemical pathways account for most degradation, and each one maps to a specific handling precaution.
Oxidation
Methionine, cysteine, and tryptophan residues are the principal oxidation targets. Methionine oxidises to the sulfoxide, adding sixteen mass units — a change readily visible by mass spectrometry. Free cysteine thiols can form unintended disulfide bonds, either within a molecule or between molecules, producing dimers and higher aggregates. Oxidation is promoted by dissolved oxygen, light, elevated temperature, and trace transition metals, which is why light protection and minimal headspace matter.
Deamidation
Asparagine and glutamine side chains hydrolyse to aspartate and glutamate, changing charge and mass by roughly one unit. Asparagine followed by glycine is a particularly labile motif, proceeding through a cyclic succinimide intermediate that can also rearrange to isoaspartate, altering the backbone geometry. Deamidation accelerates at neutral to alkaline pH and higher temperature.
Hydrolysis and aggregation
The peptide backbone itself can be cleaved by water, most readily at acidic pH and under heat, with aspartate-containing sequences especially susceptible. Separately, peptides prone to beta-sheet formation may aggregate in solution, forming assemblies that reduce the concentration of monomeric peptide and can precipitate outright.
Why the storage rules follow
Every standard precaution addresses one of these pathways. Keeping material dry suppresses hydrolysis and deamidation. Cold storage slows all of them, since reaction rates fall with temperature. Light protection limits photo-oxidation. Minimising freeze-thaw cycles avoids repeated concentration and pH shifts at the ice interface. The rules are not arbitrary conventions but direct consequences of the underlying chemistry.
References
- Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6
- Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations. Crit Rev Ther Drug Carrier Syst. 1993;10(4):307–377. PubMed 8135343
Disclosure. This article is educational and summarises published scientific literature. It is not medical advice, and it does not describe outcomes you should expect. These statements have not been evaluated by the Food and Drug Administration, and the products discussed are not intended to diagnose, treat, cure, or prevent any disease. The products discussed are supplied for laboratory and research use only and are not for human or veterinary use, administration, or consumption. For adults 21 and over.